ArticleiGIE : innovation, investigation and insights2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment.
Article in iGIE : innovation, investigation and insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Artificial intelligence (AI) may detect endoscopically active ulcerative colitis (UC) and streamline clinical trial enrollment. Here, we investigate the performance of a commercially available AI model, autoinflammatory bowel disease (AutoIBD)-UC (Virgo Surgical Video Solutions, Inc, San Francisco, Calif, USA), to detect moderate-to-severe UC in colonoscopy videos collected as part of routine clinical practice. Methods: AutoIBD-UC was applied to consecutive endoscopy videos between August 30, 2024, and October 17, 2024. Each video received an AutoIBD score (0-1); videos with scores above a predefined confidence threshold were flagged as possible moderate-to-severe UC. Flagged videos and medical records were reviewed to confirm UC diagnosis and grade Mayo endoscopic subscore (MES). Concurrently, research staff retrospectively reviewed all endoscopy reports to identify 3 cohorts: (1) 20 MES ≥2, (2) 20 non-UC inflammation, and (3) 20 screening colonoscopies. Sensitivity and specificity were calculated for all videos screened by AI. Median AutoIBD scores were compared by MES and disease extent. Results: AutoIBD-UC was applied to 2273 endoscopy videos. Twenty-one videos were flagged, 10 of which had MES ≥2. AutoIBD-UC flagged 9 of 20 videos in cohort 1 and all MES 3 videos. More procedures with extensive (4 of 8) or left-sided disease (5 of 7) were flagged compared with those with proctitis (0 of 5). Median AutoIBD-UC scores differed between MES 2 (0.437; interquartile range [IQR], 0.270-0.571) and MES 3 (0.690; IQR, 0.607-0.765; Conclusions: AutoIBD-UC accurately detects moderate-to-severe UC with moderate sensitivity and high specificity. Larger studies are necessary to evaluate AutoIBD-UC's utility as a recruitment aid compared to standard practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.